Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
LIM domain-binding protein 2 (LDB2) is a nuclear adaptor and member of the LIM-domain binding family characterized by an amino-terminal homodimerization domain and a carboxy-terminal LIM interaction domain[1][3]. LDB2 acts as an adapter molecule for the assembly of transcriptional regulatory complexes, binding to more than 10,000 genomic targets and interacting with transcription factors such as LHX2, LMO2, LMO3, LMO4, SSBP2/3/4, and RLIM[3]. LDB2 is integral to transcriptional regulation in neuronal cells and plays a significant role in gene networks associated with mental disorders like schizophrenia and bipolar disorder[3]. Its functional disruption leads to behavioral abnormalities in animal models, reflecting its importance in brain development and function. LDB2 also regulates the expression of other genes (e.g., DLL4) and is implicated in various biological and disease processes[5].
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on LIM domain-binding protein 2 (LDB2).